The functional role of reactive stroma in benign prostatic hyperplasia

Differentiation

Volumn 82, Issue 4-5, 2011, Pages 200-210

  Schauer, Isaiah G ^a,b   Rowley, David R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BPH; CXCL12; Hyperplasia; IL 8; Reactive stroma; Tenascin C

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; ELOCALCITOL; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 8; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE ELASTASE; PHOSPHATIDYLINOSITOL 3 KINASE; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1ALPHA; TENASCIN; TRANSFORMING GROWTH FACTOR BETA;

CANCER GROWTH; CELL INTERACTION; CELL PROLIFERATION; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EMBRYO DEVELOPMENT; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROGENESIS; HUMAN; MYOFIBROBLAST; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; REACTIVE STROMA; REVIEW; STROMA; STROMA CELL; TIGHT JUNCTION; WOUND HEALING;

CHEMOKINES; EPITHELIUM; EXTRACELLULAR MATRIX; GONADAL STEROID HORMONES; HUMANS; INFLAMMATION; INTERLEUKIN-8; MALE; MESODERM; MYOFIBROBLASTS; PROSTATE; PROSTATIC HYPERPLASIA; STROMAL CELLS; WOUND HEALING;

EID: 80051787167     PISSN: 03014681     EISSN: 14320436     Source Type: Journal    
DOI: 10.1016/j.diff.2011.05.007     Document Type: Review

References (153)

1. Abdel-Malak N.A., et al. Angiopoietin-1 promotes endothelial cell proliferation and migration through AP-1-dependent autocrine production of interleukin-8. Blood 2008, 111(8):4145-4154.
2. Addison C.L., et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+CXC chemokine-induced angiogenic activity. J. Immunol. 2000, 165(9):5269-5277.
3. Adorini L., et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J. Steroid. Biochem. Mol. Biol. 2007, 103(3-5):689-693.
4. Araki S., et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 2007, 67(14):6854-6862.
5. Aryal M., et al. Oxidative stress in patients with benign prostate hyperplasia. JNMA J. Nepal Med. Assoc. 2007, 46(167):103-106.
6. Ayala G., et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin. Cancer Res. 2003, 9(13):4792-4801.
7. Aydin A., et al. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin. Biochem. 2006, 39(2):176-179.
8. Begley L., et al. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell 2005, 4(6):291-298.
9. Begley L.A., et al. CXCL12 activates a robust transcriptional response in human prostate epithelial cells. J. Biol. Chem. 2007, 282(37):26767-26774.
10. Begley L.A., et al. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine 2008, 43(2):194-199.
11. Belperio J.A., et al. CXC chemokines in angiogenesis. J. Leukoc. Biol. 2000, 68(1):1-8.
12. Berger A.P., et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int. 2005, 96(7):1073-1078.
13. Berry S.J., et al. The development of human benign prostatic hyperplasia with age. J. Urol. 1984, 132(3):474-479.
14. Bhattacharyya S., et al. Toll-like receptor 4 mediates induction of the Bcl10-NFkappaB-interleukin-8 inflammatory pathway by carrageenan in human intestinal epithelial cells. J. Biol. Chem. 2008, 283(16):10550-10558.
15. Bianchi-Frias D., et al. The effects of aging on the molecular and cellular composition of the prostate microenvironment. PLoS. One 2010, 5:9.
16. Boncoeur E., et al. Oxidative stress induces extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase in cystic fibrosis lung epithelial cells: potential mechanism for excessive IL-8 expression. Int. J. Biochem. Cell Biol. 2008, 40(3):432-446.
17. Bozic C.R., et al. The murine interleukin 8 type B receptor homologue and its ligands. Expression and biological characterization. J. Biol. Chem. 1994, 269(47):29355-29358.
18. Buchholz K.R., Stephens R.S. The extracellular signal-regulated kinase/mitogen-activated protein kinase pathway induces the inflammatory factor interleukin-8 following Chlamydia trachomatis infection. Infect. Immun. 2007, 75(12):5924-5929.
19. Burger J.A. CXCR4 in acute myelogenous leukemia (AML): when too much attraction is bad for you. Leuk. Res. 2009, 33(6):747-748.
20. Campisi J. Cellular senescence: putting the paradoxes in perspective. Curr. Opin. Genet. Dev. 2011, 21(1):107-112.
21. Cantini, L.P., et al., Profibrotic role of myostatin in Peyronie's disease. J. Sex. Med., 2008.
22. Castro P., et al. Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 2004, 60(2):153-159.
23. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol. Cell. Biochem. 2003, 253(1-2):89-101.
24. Chiquet M., Sarasa-Renedo A., Tunc-Civelek V. Induction of tenascin-C by cyclic tensile strain versus growth factors: distinct contributions by Rho/ROCK and MAPK signaling pathways. Biochim. Biophys. Acta 2004, 1693(3):193-204.
25. Cho K.S., et al. The overlooked cause of benign prostatic hyperplasia: prostatic urethral angulation. Med. Hypotheses 2008, 70(3):532-535.
26. Claus S., et al. Immunohistochemical determination of age related proliferation rates in normal and benign hyperplastic human prostates. Urol. Res. 1993, 21(5):305-308.
27. Coppe J.P., et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol.. 5 2010, 99-118.
28. Cordon-Cardo C., et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J. Natl. Cancer Inst. 1998, 90(17):1284-1291.
29. Davalos A.R., et al. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev. 2010, 29(2):273-283.
30. De Wever O., et al. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J. 2004, 18(9):1016-1018.
31. Delongchamps N.B., et al. Evaluation of prostatitis in autopsied prostates-is chronic inflammation more associated with benign prostatic hyperplasia or cancer?. J. Urol. 2008, 179(5):1736-1740.
32. Devalaraja R.M., et al. Delayed wound healing in CXCR2 knockout mice. J. Invest. Dermatol. 2000, 115(2):234-244.
33. Dhawan P., Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol. 2002, 72(1):9-18.
34. Di Silverio F., et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur. Urol. 2003, 43(2):164-175.
35. Douglass A., et al. Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury. J. Hepatol 2008.
36. Eaton A.D., Xu D., Garside P. Administration of exogenous interleukin-18 and interleukin-12 prevents the induction of oral tolerance. Immunology 2003, 108(2):196-203.
37. Eck S.M., et al. Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer. J. Autoimmun. 2009, 33(3-4):214-221.
38. El-Karef A., et al. Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J. Pathol. 2007, 211(1):86-94.
39. Eyman D., et al. CCL5 secreted by senescent aged fibroblasts induces proliferation of prostate epithelial cells and expression of genes that modulate angiogenesis. J. Cell. Physiol. 2009, 220(2):376-381.
40. Farina, G., et al., Cartilage-oligomeric-matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor-{beta}. Ann. Rheum. Dis., 2008.
41. Fujinaga K., et al. Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts. J. Thorac. Cardiovasc. Surg. 2004, 128(3):357-363.
42. Gangadhar T., Nandi S., Salgia R. The role of chemokine receptor CXCR4 in lung cancer. Cancer Biol. Ther. 2010, 9(6):409-416.
43. Gao X., et al. Connective tissue growth factor stimulates renal cortical myofibroblast-like cell proliferation and matrix protein production. Wound Repair Regen. 2008, 16(3):408-415.
44. Gebb S.A., et al. Fetal oxygen tension promotes tenascin-C-dependent lung branching morphogenesis. Dev. Dyn. 2005, 234(1):1-10.
45. Gerard C., Rollins B.J. Chemokines and disease. Nat. Immunol. 2001, 2(2):108-115.
46. Giri D., Ittmann M. Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. Am. J. Pathol. 2000, 157(1):249-255.
47. Giri D., Ittmann M. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am. J. Pathol. 2001, 159(1):139-147.
48. Gladson C.L., Welch D.R. New insights into the role of CXCR4 in prostate cancer metastasis. Cancer Biol. Ther. 2008, 7(11):1849-1851.
49. Govindaraju V., et al. Interleukin-8: novel roles in human airway smooth muscle cell contraction and migration. Am. J. Physiol. Cell Physiol. 2006, 291(5):C957-C965.
50. Gradini R., et al. Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J. Pathol. 1999, 189(2):224-229.
51. Hallgren J., et al. Pulmonary CXCR2 regulates VCAM-1 and antigen-induced recruitment of mast cell progenitors. Proc. Natl. Acad. Sci. USA 2007, 104(51):20478-20483.
52. Handisurya A., et al. Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate 2001, 49(4):251-262.
53. Heidemann J., et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J. Biol. Chem. 2003, 278(10):8508-8515.
54. Hinton C.V., Avraham S., Avraham H.K. Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin. Exp. Metastasis 2010, 27(2):97-105.
55. Hirota Y., et al. Activation of protease-activated receptor 2 stimulates proliferation and interleukin (IL)-6 and IL-8 secretion of endometriotic stromal cells. Hum. Reprod. 2005, 20(12):3547-3553.
56. Hochreiter W.W., Weidner W. Prostatitis-a frequently unrecognized disease. Ther. Umsch. 2006, 63(2):117-121.
57. Hulka B.S., et al. Serum hormone levels among patients with prostatic carcinoma or benign prostatic hyperplasia and clinic controls. Prostate 1987, 11(2):171-182.
58. Hunter D., Davies J. An overview of prostate gland development. The Glandular Organ Development Database 1997, Medical Research Council.
59. Ilunga K., et al. Co-stimulation of human breast cancer cells with transforming growth factor-beta and tenascin-C enhances matrix metalloproteinase-9 expression and cancer cell invasion. Int. J. Exp. Pathol. 2004, 85(6):373-379.
60. Ingham K.C., Brew S.A., Erickson H.P. Localization of a cryptic binding site for tenascin on fibronectin. J. Biol. Chem. 2004, 279(27):28132-28135.
61. Inoue K., et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin. Cancer Res. 2000, 6(5):2104-2119.
62. Isaacs J.T. Etiology of benign prostatic hyperplasia. Eur. Urol. 1994, 25(Suppl. 1):6-9.
63. Ishii K., et al. Role of stromal tenascin-C in mouse prostatic development and epithelial cell differentiation. Dev. Biol. 2008, 324(2):310-319.
64. Jang J.H., Chung C.P. Tenascin-C promotes cell survival by activation of Akt in human chondrosarcoma cell. Cancer Lett. 2005, 229(1):101-105.
65. Jang J.H., et al. Identification and kinetics analysis of a novel heparin-binding site (KEDK) in human tenascin-C. J. Biol. Chem. 2004, 279(24):25562-25566.
66. Jinnin M., et al. Tenascin-C upregulation by transforming growth factor-beta in human dermal fibroblasts involves Smad3, Sp1, and Ets1. Oncogene 2004, 23(9):1656-1667.
67. Joseph T., Look D., Ferkol T. NF-kappaB activation and sustained IL-8 gene expression in primary cultures of cystic fibrosis airway epithelial cells stimulated with Pseudomonas aeruginosa. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 288(3):L471-L479.
68. Jotzu C., et al. Adipose tissue-derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumor-derived factors. Anal. Cell. Pathol. (Amst) 2010, 33(2):61-79.
69. Jung Y.D., et al. Role of P38 MAPK, AP-1, and NF-kappaB in interleukin-1beta-induced IL-8 expression in human vascular smooth muscle cells. Cytokine 2002, 18(4):206-213.
70. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol 2005, 5(10):749-759.
71. Kasturi S., Russell S., McVary K.T. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr. Urol. Rep. 2006, 7(4):288-292.
72. Khadra A., et al. Interleukin-8 levels in seminal plasma in chronic prostatitis/chronic pelvic pain syndrome and nonspecific urethritis. BJU Int. 2006, 97(5):1043-1046.
73. Kim S.J., et al. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 2001, 3(1):33-42.
74. Kim S.W., et al. Tid1 negatively regulates the migratory potential of cancer cells by inhibiting the production of interleukin-8. Cancer Res. 2005, 65(19):8784-8791.
75. Klezovitch O., et al. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004, 6(2):185-195.
76. Kohnen P.W., Drach G.W. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J. Urol. 1979, 121(6):755-760.
77. Kojima Y., et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. USA 2010, 107(46):20009-20014.
78. Kooijman R., et al. Regulation of interleukin-8 expression in human prostate cancer cells by insulin-like growth factor-I and inflammatory cytokines. Growth Horm. IGF Res. 2007, 17(5):383-391.
79. Koyama Y., et al. Effect of tenascin-C deficiency on chemically induced dermatitis in the mouse. J. Invest. Dermatol. 1998, 111(6):930-935.
80. Kramer G., Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia?. Curr. Opin. Urol. 2006, 16(1):25-29.
81. Kramer G., Mitteregger D., Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur. Urol. 2007, 51(5):1202-1216.
82. Lane H.C., Anand A.R., Ganju R.K. Cbl and Akt regulate CXCL8-induced and CXCR1- and CXCR2-mediated chemotaxis. Int. Immunol. 2006, 18(8):1315-1325.
83. Le Quement, C., et al., Mmp-12 induces Il-8/Cxcl8 secretion through Egfr and Erk1/2 activation in epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol., 2008.
84. Lee K.L., Peehl D.M. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J. Urol. 2004, 172(5 Pt 1):1784-1791.
85. Li A., et al. Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis 2005, 8(1):63-71.
86. Li D.Q., et al. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp. Eye Res. 2006, 82(4):588-596.
87. Li P.J., et al. Effect of hypertension on cell proliferation and apoptosis in benign prostatic hyperplasia. Zhonghua Nan Ke Xue 2005, 11(2):94-97.
88. Li Q., et al. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002, 111(5):635-646.
89. Lin V.K., et al. Prostatic stromal cells derived from benign prostatic hyperplasia specimens possess stem cell like property. Prostate 2007, 67(12):1265-1276.
90. Macoska J.A., et al. Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA. Prostate 2008, 68(4):442-452.
91. Malgorzata Goczalik I., et al. The activation of IL-8 receptors in cultured guinea pig Muller glial cells is modified by signals from retinal pigment epithelium. J. Neuroimmunol. 2005, 161(1-2):49-60.
92. Marton I.J., et al. Differential in situ distribution of interleukin-8, monocyte chemoattractant protein-1 and Rantes in human chronic periapical granuloma. Oral Microbiol. Immunol. 2000, 15(1):63-65.
93. McAlhany S.J., et al. Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model. Cancer Res. 2003, 63(18):5859-5865.
94. McKean D.M., et al. FAK induces expression of Prx1 to promote tenascin-C-dependent fibroblast migration. J. Cell Biol. 2003, 161(2):393-402.
95. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol. Clin. North Am. 1990, 17(3):477-486.
96. McNeal J.E. Origin and evolution of benign prostatic enlargement. Invest. Urol. 1978, 15(4):340-345.
97. McNeal J.E. The zonal anatomy of the prostate. Prostate 1981, 2(1):35-49.
98. McVary K.T., et al. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol. 2005, 174(4 Pt 1):1327-1433.
99. Mishra P., Banerjee D., Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J. Leukoc. Biol. 2011, 89(1):31-39.
100. Mishra V.C., et al. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia?. BJU Int. 2007, 100(2):327-331.
101. Morrison C., Thornhill J., Gaffney E. The connective tissue framework in the normal prostate, BPH and prostate cancer: analysis by scanning electron microscopy after cellular digestion. Urol. Res. 2000, 28(5):304-307.
102. Mukaida N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003, 284(4):L566-L577.
103. Nakao N., et al. Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture. Am. J. Pathol. 1998, 152(5):1237-1245.
104. Nakhla A.M., et al. Estradiol causes the rapid accumulation of cAMP in human prostate. Proc. Natl. Acad. Sci. USA 1994, 91(12):5402-5405.
105. Nickel J.C. Inflammation and benign prostatic hyperplasia. Urol. Clin. North Am. 2008, 35(1):109-115. vii.
106. Nickel J.C., et al. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999, 84(9):976-981.
107. Obata H., Tsuru T. Corneal wound healing from the perspective of keratoplasty specimens with special reference to the function of the Bowman layer and Descemet membrane. Cornea 2007, 26(9 Suppl. 1):S82-S89.
108. Ooi L.L., Dunstan C.R. CXCL12/CXCR4 axis in tissue targeting and bone destruction in cancer and multiple myeloma. J. Bone Miner. Res. 2009, 24(7):1147-1149.
109. Ozden C., et al. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur. Urol. 2007, 51(1):199-203. discussion 204-6.
110. Penna G., et al. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur. Urol. 2007, 51(2):524-533. discussion 533.
111. Penna G., et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate 2009, 69(5):480-493.
112. Phan S.H. Biology of fibroblasts and myofibroblasts. Proc. Am. Thorac. Soc. 2008, 5(3):334-337.
113. Powell D.W., et al. Myofibroblasts. I. Paracrine cells important in health and disease. Am. J. Physiol. 1999, 277(1 Pt 1):C1-C9.
114. Price H., McNeal J.E., Stamey T.A. Evolving patterns of tissue composition in benign prostatic hyperplasia as a function of specimen size. Hum. Pathol. 1990, 21(6):578-585.
115. Profita M., et al. Acetylcholine mediates the release of IL-8 in human bronchial epithelial cells by a NFkB/ERK-dependent mechanism. Eur. J. Pharmacol. 2008, 582(1-3):145-153.
116. Ratner A.J., et al. Epithelial cells are sensitive detectors of bacterial pore-forming toxins. J. Biol. Chem. 2006, 281(18):12994-12998.
117. Risbridger G.P., Almahbobi G.A., Taylor R.A. Early prostate development and its association with late-life prostate disease. Cell Tissue Res. 2005, 322(1):173-181.
118. Roberts R.O., et al. Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia. Prostate 2006, 66(4):392-404.
119. Rodriguez-Pena, A.B., et al., Activation of Erk1/2 and Akt following unilateral ureteral obstruction. Kidney Int., 2008.
120. Roth-Kleiner M., Hirsch E., Schittny J.C. Fetal lungs of tenascin-C-deficient mice grow well, but branch poorly in organ culture. Am. J. Respir. Cell Mol. Biol. 2004, 30(3):360-366.
121. Rowley D.R. What might a stromal response mean to prostate cancer progression?. Cancer Metastasis Rev. 1998, 17(4):411-419.
122. Royuela M., et al. IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis. Growth Factors 2000, 18(2):135-146.
123. Saigal C.S., Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J. Urol. 2005, 173(4):1309-1313.
124. Sampson N., Madersbacher S., Berger P. Pathophysiology and therapy of benign prostatic hyperplasia. Wien. Klin. Wochenschr. 2008, 120(13-14):390-401.
125. Schauer I.G., et al. Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology 2008, 72(1):205-213.
126. Schauer I.G., Ressler S.J., Rowley D.R. Keratinocyte-derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model. Prostate 2009, 69(4):373-384.
127. Sciarra A., et al. Prostate growth and inflammation. J. Steroid. Biochem. Mol. Biol. 2008, 108(3-5):254-260.
128. Sciarra F., Toscano V. Role of estrogens in human benign prostatic hyperplasia. Arch. Androl. 2000, 44(3):213-220.
129. Shimizu K. Pancreatic stellate cells: molecular mechanism of pancreatic fibrosis. J. Gastroenterol. Hepatol. 2008, 23(Suppl. 1):S119-S121.
130. Smythies L.E., et al. Mucosal IL-8 and TGF-beta recruit blood monocytes: evidence for cross-talk between the lamina propria stroma and myeloid cells. J. Leukoc. Biol. 2006, 80(3):492-499.
131. Steiner G.E., et al. The picture of the prostatic lymphokine network is becoming increasingly complex. Rev. Urol. 2002, 4(4):171-177.
132. Steiner G.E., et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab. Invest. 2003, 83(8):1131-1146.
133. Tamaoki M., et al. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am. J. Pathol. 2005, 167(1):71-80.
134. Tobler A., et al. Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts. Blood 1992, 79(1):45-51.
135. True L.D., et al. The accumulation of versican in the nodules of benign prostatic hyperplasia. Prostate 2009, 69(2):149-158.
136. Tuxhorn J.A., Ayala G.E., Rowley D.R. Reactive stroma in prostate cancer progression. J. Urol. 2001, 166(6):2472-2483.
137. Tuxhorn J.A., et al. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res. 2002, 8(9):2912-2923.
138. Uehara H., et al. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 2005, 64(1):40-49.
139. Untergasser G., Madersbacher S., Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp. Gerontol. 2005, 40(3):121-128.
140. Vazquez-Martin A., Colomer R., Menendez J.A. Her-2/neu-induced "cytokine signature" in breast cancer. Adv. Exp. Med. Biol. 2008, 617:311-319.
141. Wang L., et al. Chronic inflammation in benign prostatic hyperplasia: Implications for therapy. Med. Hypotheses 2008, 70(5):1021-1023.
142. Waugh D.J., et al. Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front Biosci. 2008, 13:4595-4604.
143. Wilson J.D., Griffin J.E. The use and misuse of androgens. Metabolism 1980, 29(12):1278-1295.
144. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001, 12(4):375-391.
145. Yadav V.R., et al. Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. J. Mol. Med. 2010, 88(12):1243-1253.
146. Yang F., et al. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 2005, 65(19):8887-8895.
147. Yang Y., et al. Tenascin-C deposition requires beta3 integrin and Src. Biochem. Biophys. Res. Commun. 2004, 322(3):935-942.
148. Yao C., et al. Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int. J. Cancer 2007, 121(9):1949-1957.
149. Yi F.X., et al. Risk factors for prostatic inflammation extent and infection in benign prostatic hyperplasia. Asian J. Androl. 2006, 8(5):621-627.
150. Yun A.J., Doux J.D. Opening the floodgates: benign prostatic hyperplasia may represent another disease in the compendium of ailments caused by the global sympathetic bias that emerges with aging. Med. Hypotheses 2006, 67(2):392-394.
151. Zhao H., Peehl D.M. Tumor-promoting phenotype of CD90hi prostate cancer-associated fibroblasts. Prostate 2009, 69(9):991-1000.
152. Zhao M., et al. Arrestin regulates MAPK activation and prevents NADPH oxidase-dependent death of cells expressing CXCR2. J. Biol. Chem. 2004, 279(47):49259-49267.
153. van der Heul-Nieuwenhuijsen L., et al. Gene expression profiling of the human prostate zones. BJU Int. 2006, 98(4):886-897.